LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile

Journal of Internal Medicine

Volumn 272, Issue 5, 2012, Pages 452-464

  Hu, X ^a   Steffensen, K R ^a   Jiang, Z Y ^b   Parini, P ^a   Gustafsson, J A ^a,c   Gafvels M ^a   Eggertsen, G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c University of Houston   (United States)

Author keywords

Cholesterol; Cholesterol absorption; HDL; Intestine; Liver X receptor

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; APOLIPOPROTEIN B; BILE ACID; CARRIER PROTEIN; CHOLESTEROL; LIPOPROTEIN; LIVER X RECEPTOR BETA; PROTEIN NPC11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; GENOTYPE; HYDROPHOBICITY; INTESTINE ABSORPTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR GENE; STEROL EXCRETION; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOATES; BENZYLAMINES; BILE; CHOLESTEROL; CHOLESTEROL, DIETARY; INTESTINAL ABSORPTION; INTESTINE, SMALL; LIPID METABOLISM; LIPOPROTEINS; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; ORPHAN NUCLEAR RECEPTORS; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84867904787     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02529.x     Document Type: Article

References (42)

1. Davis HR Jr, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 2011; 215: 266-78.
2. Slatis K, Gafvels M, Kannisto K et al. Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res 2010; 51: 3289-98.
3. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008; 6: 447-70.
4. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8.
5. Brown WV. Cholesterol absorption inhibitors: defining new options in lipid management. Clin Cardiol 2003; 26: 259-64.
6. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.
7. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
8. Li-Hawkins J, Gafvels M, Olin M et al. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J Clin Invest 2002; 110: 1191-200.
9. Wang DQ, Tazuma S, Cohen DE, Carey MC. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol 2003; 285: G494-502.
10. Woollett LA, Buckley DD, Yao L et al. Cholic acid supplementation enhances cholesterol absorption in humans. Gastroenterology 2004; 126: 724-31.
11. Woollett LA, Wang Y, Buckley DD et al. Micellar solubilisation of cholesterol is essential for absorption in humans. Gut 2006; 55: 197-204.
12. Altmann SW, Davis HR Jr, Zhu LJ et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
13. Tang WQ, Ma YY, Jia L, Ioannou YA, Davies JP, Yu LQ. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler Thromb Vasc Biol 2008; 28: 448-54.
14. Korach-Andre M, Parini P, Larsson L, Arner A, Steffensen KR, Gustafsson JA. Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57Bl/6 female mice. Am J Physiol Endocrinol Metab 2010; 298: E167-78.
15. Calkin AC, Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1513-8.
16. Quinet EM, Savio DA, Halpern AR et al. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting. Mol Pharmacol 2006; 70: 1340-9.
17. Yu LQ, York J, von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem 2003; 278: 15565-70.
18. Repa JJ, Turley SD, Lobaccaro JA et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-9.
19. Plosch T, Bloks VW, Terasawa Y et al. Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor. Gastroenterology 2004; 126: 290-300.
20. Lo Sasso G, Murzilli S, Salvatore L et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab 2010; 12: 187-93.
21. Alberti S, Schuster G, Parini P et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 2001; 107: 565-73.
22. Schwarz M, Russell DW, Dietschy JM, Turley SD. Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J Lipid Res 1998; 39: 1833-43.
23. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
24. Parini P, Johansson L, Broijersen A, Angelin B, Rudling M. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 2006; 36: 98-104.
25. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009; 296: E1183-94.
26. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607-14.
27. Timmins JM, Lee JY, Boudyguina E et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 115: 1333-42.
28. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res 2009; 50: 2340-57.
29. Greenberg ME, Smith JD, Sehayek E. Moderately decreased cholesterol absorption rates are associated with a large atheroprotective effect. Arterioscler Thromb Vasc Biol 2009; 29: 1745-50.
30. Kruit JK, Plosch T, Havinga R et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 2005; 128: 147-56.
31. van der Veen JN, van Dijk TH, Vrins CL et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem 2009; 284: 19211-9.
32. Peet DJ, Turley SD, Ma W et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998; 93: 693-704.
33. Beltowski J. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc Ther 2008; 26: 297-316.
34. Duval C, Touche V, Tailleux A et al. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun 2006; 340: 1259-63.
35. Jia L, Ma Y, Rong S et al. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J Lipid Res 2010; 51: 3135-44.
36. Davis HR Jr, Hoos LM, Tetzloff G et al. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler Thromb Vasc Biol 2007; 27: 841-9.
37. Ge L, Wang J, Qi W et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008; 7: 508-19.
38. Xie C, Li N, Chen ZJ, Li BL, Song BL. The small GTPase Cdc42 interacts with Niemann-Pick C1 Like 1 (NPC1L1) and controls its movement from endocytic recycling compartment to plasma membrane in a cholesterol dependent manner. J Biol Chem 2011; 286: 35933-42.
39. Brunham LR, Kruit JK, Hayden MR, Verchere CB. Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. Curr Diab Rep 2010; 10: 55-60.
40. Wang J, Einarsson C, Murphy C et al. Studies on LXR- and FXR-mediated effects on cholesterol homeostasis in normal and cholic acid-depleted mice. J Lipid Res 2006; 47: 421-30.
41. Goodwin BJ, Zuercher WJ, Collins JL. Recent advances in liver X receptor biology and chemistry. Curr Top Med Chem 2008; 8: 781-91.
42. Bradley MN, Hong C, Chen M et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest 2007; 117: 2337-46.